Inflammatory joint disease in cats

Lemetayer, Julie Denise; Taylor, Susan

doi:10.1177/1098612x14539086

Cited by 16 publications

(12 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 1 There are only two previous reports of feline IMPA. 2 IMPA is a non-infectious inflammatory joint disorder that is diagnosed by the presence of neutrophil-rich synovial fluid collected by arthrocentesis. It is categorised as an immune-mediated non-erosive polyarthritis.…”

Section: Introductionmentioning

confidence: 99%

“…It is categorised as an immune-mediated non-erosive polyarthritis. 1 , 2 Differential diagnoses of immune-mediated non-erosive polyarthritis are reactive polyarthritis and systemic lupus erythematosus (SLE). 2 Therefore, the diagnosis of IMPA is made as primary immune-mediated non-erosive polyarthritis by excluding SLE.…”

Section: Introductionmentioning

confidence: 99%

“… 1 , 2 Differential diagnoses of immune-mediated non-erosive polyarthritis are reactive polyarthritis and systemic lupus erythematosus (SLE). 2 Therefore, the diagnosis of IMPA is made as primary immune-mediated non-erosive polyarthritis by excluding SLE. 2 Corticosteroids are considered the first line of treatment and should be combined with other immunosuppressants if a single agent is not effective.…”

Section: Introductionmentioning

confidence: 99%

“… 2 Therefore, the diagnosis of IMPA is made as primary immune-mediated non-erosive polyarthritis by excluding SLE. 2 Corticosteroids are considered the first line of treatment and should be combined with other immunosuppressants if a single agent is not effective. 1 , 2 In cats, additional reported immunosuppressants used for immune-mediated polyarthritis are as follows: leflunomide (LEF), ciclosporin A (CsA), methotrexate (MTX) and chlorambucil.…”

Section: Introductionmentioning

confidence: 99%

“… 1 , 2 In cats, additional reported immunosuppressants used for immune-mediated polyarthritis are as follows: leflunomide (LEF), ciclosporin A (CsA), methotrexate (MTX) and chlorambucil. 2 …”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Successful treatment and long-term follow up of idiopathic immune-mediated polyarthritis with mycophenolate mofetil in a cat

Tamura

Nagamoto

Segawa³

et al. 2020

Journal of Feline Medicine and Surgery Open Reports

View full text Add to dashboard Cite

Case summary A 7-year-old neutered male Norwegian Forest Cat was presented with decreased appetite and activity, weight loss, fever, neutrophilia and hyperglobulinaemia. A physical examination showed painful stifle joints and enlarged popliteal lymph nodes. Blood examination showed neutrophilia, hyperglobulinaemia and increased serum amyloid A. Urinalysis, thoracic and abdominal radiographs, and abdominal ultrasonography were unremarkable. Synovial fluid from the knee joints had diminished viscosity and revealed neutrophilic inflammation on the smear. There was no evidence of infection in a microbiological culture of the synovial fluid. A diagnosis of idiopathic immune-mediated polyarthritis (IMPA) was made. Prednisolone was initiated at 2 mg/kg q24h PO and tapered with additional immunosuppressants (leflunomide, ciclosporin A and methotrexate); however, prednisolone could not be discontinued. Informed consent was obtained from the owner and mycophenolate mofetil (MMF) at a dosage of 10 mg/kg q12h PO was initiated on day 798. There were no adverse effects of MMF and prednisolone was discontinued on day 1183. Clinical signs resolved and the cat’s general condition remained stable with MMF alone at a dosage of 10 mg/kg q48h PO on day 1600. Relevance and novel information There is limited information describing feline IMPA and its treatment options other than the use of prednisolone. This is the first report of the successful treatment and long-term follow-up of feline IMPA with MMF. MMF may be a safe and effective option as an additional immunosuppressant in feline IMPA.

show abstract

Section: Introductionmentioning

confidence: 99%